RT Journal Article
SR Electronic
T1 Efficacy of Proxalutamide in Hospitalized COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Clinical Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.22.21259318
DO 10.1101/2021.06.22.21259318
A1 Flávio Adsuara Cadegiani
A1 Daniel do Nascimento Fonseca
A1 John McCoy
A1 Ricardo Ariel Zimerman
A1 Fatima Nadeem Mirza
A1 Michael do Nascimento Correia
A1 Renan Nascimento Barros
A1 Dirce Costa Onety
A1 Karla Cristina Petruccelli Israel
A1 Brenda Gomes de Almeida
A1 Emilyn Oliveira Guerreiro
A1 José Erique Miranda Medeiros
A1 Raquel Neves Nicolau
A1 Luiza Fernanda Mendonça Nicolau
A1 Rafael Xavier Cunha
A1 Maria Fernanda Rodrigues Barroco
A1 Patrícia Souza da Silva
A1 Gabriel de Souza Ferreira
A1 Flavio Renan Paula da Costa Alcântara
A1 Ângelo Macedo Ribeiro
A1 Felipe Oliveira de Almeida
A1 Adailson Antonio de Souza Silva
A1 Suzyane Serfaty do Rosario
A1 Raysa Wanzeller de Souza Paulain
A1 Alessandra Reis
A1 Marissa Li
A1 Claudia Elizabeth Thompson
A1 Gerard J. Nau
A1 Carlos Gustavo Wambier
A1 Andy Goren
YR 2021
UL http://medrxiv.org/content/early/2021/06/22/2021.06.22.21259318.abstract
AB Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity is mediated by the androgen-promoted protease, transmembrane protease, serine 2 (TMPRSS2). Previously, we have shown that treatment with proxalutamide, a non-steroidal androgen receptor antagonist, accelerates viral clearance and clinical remission in outpatients with coronavirus disease 2019 (COVID-19) compared to placebo. The effects in hospitalized COVID-19 patients were unknown.Methods Men and women hospitalized but not requiring mechanical ventilation were randomized (1:1 ratio) to receive 300 mg of proxalutamide per day or placebo for 14 days. The study was conducted at eight sites in the state of Amazonas, Brazil. The primary outcome measure was the clinical status (8-point ordinal scale) at 14-days post-randomization. The primary efficacy endpoint was the 14-day recovery ratio (alive hospital discharge [scores 1, 2]).Findings A total of 645 patients were randomized (317 received proxalutamide, 328 placebo) and underwent intention-to-treat analysis. The 14-day median ordinal scale score in the proxalutamide group was 1 (interquartile range [IQR]=1–2) versus 7 (IQR=2–8) for placebo, P<0.001. The 14-day recovery rate was 81.4% for proxalutamide and 35.7% for placebo (recovery ratio, 2.28; 95% CI 1.95–2.66 [P<0.001]). The 28-day all-cause mortality rate was 11.0% for proxalutamide versus 49.4% for placebo (hazard ratio, 0.16; 95% CI 0.11–0.24). The median post-randomization time to recovery was 5 days (IQR=3– 8) for proxalutamide versus 10 days (IQR=6–15) for placebo.Interpretation Hospitalized COVID-19 patients not requiring mechanical ventilation receiving proxalutamide had a 128% higher recovery rate than those treated with placebo. All-cause mortality was reduced by 77.7% over 28 days. (ClinicalTrials.gov number, NCT04728802).Competing Interest StatementKintor Pharmaceuticals, Ltd. manufactures and plans to market proxalutamide for COVID-19. Applied Biology, Inc. has patents pending regarding antiandrogen therapy for COVID-19. Dr. Goren, Dr. McCoy, and Dr. Li are employees of Applied Biology, Inc. Dr. Cadegiani has served as a clinical director for Applied Biology, Inc. Dr. Wambier has served as an advisor to Applied Biology, Inc. The other authors have no conflict of interest to declare.Clinical TrialNCT04728802Funding StatementThis investigator-initiated trial was supported by an unconditional research grant from Kintor Pharmaceuticals, Ltd. to Applied Biology, Inc., which provided study drugs at no cost. Kintor Pharmaceuticals, Ltd. had no role in the design of the study, data collection, analysis, interpretation of data, or in writing the manuscript, and provided no financial support to the hospitals, or to investigators.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by an ethics committee and registered in clinicaltrials.gov (NCT04728802), and also approved by Brazilian National Ethics Committee, approval number 4.513.425; CAAE 41909121.0.0000.5553.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDataset is available under request and specific justification.